Dabigatran etexilate: Management in acute ischemic stroke

Parisa P. Javedani, Zane Z. Horowitz, Wayne M. Clark, Helmi L. Lutsep

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


A 54-year-old man treated with dabigatran experienced new onset of a stroke with a score of 9 on the National Institutes of Health Stroke Scale. Administration of recombinant tissue plasminogen activator (rtPA) was not recommended because of the dabigatran therapy. Angiography showed occlusion of the left middle cerebral artery by an embolic thrombus. Suction thrombectomy achieved flow through the inferior division of the artery. Computed tomography of the head showed possible intracranial hemorrhage, and dabigatran reversal was attempted with prothrombin complex concentrate and recombinant factor VIIa. Coagulation studies before administration of the reversal blood products showed a partial thromboplastin time of 30.3 seconds; 1 hour after administration, the partial thromboplastin time was 28.5 seconds. No evidence of intracranial hemorrhage was apparent on repeated computed tomography scans of the brain. He was discharged with aspirin and warfarin and a stroke score of 8.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalAmerican Journal of Critical Care
Issue number2
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Critical Care


Dive into the research topics of 'Dabigatran etexilate: Management in acute ischemic stroke'. Together they form a unique fingerprint.

Cite this